Andrew Cheng - 16 Dec 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President & CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
16 Dec 2022
Transactions value $
$5,228
Form type
4
Filing time
20 Dec 2022, 18:46:56 UTC
Previous filing
13 Dec 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $5.23K +8.5K +2.34% $0.62* 371K 16 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +87.2K +50% $0.00 262K 16 Dec 2022 Common Stock 87.2K $21.10 Direct F1
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -8.5K -4.13% $0.00 197K 16 Dec 2022 Common Stock 8.5K $0.62 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On December 16, 2022, the third performance milestone was achieved, resulting in the vesting of 87,220 shares underlying such option.
F2 The options are vested and currently exercisable.